Antares Pharma Inc

NASDAQ:ATRS  
3.29
-0.06 (-1.79%)
Products, Earnings Announcements

Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue

Published: 01/11/2022 12:46 GMT
Antares Pharma Inc (ATRS) - Antares Pharma Announces Positive Results From Phase I Study for Atrs-1902 for Adrenal Crisis Rescue.
Antares Pharma Inc - Phase I Cross-over Study Met Its Primary Objective Showing Atrs-1902 Delivered Comparable Pharmacokinetic Profile to Solu-cortef.
Antares Pharma Inc - Study Also Demonstrated That Atrs-1902 Was Safe and Well Tolerated.
Antares Pharma Inc - Expect to File 505(b)(2) NDA With FDA by End of 2022.
Antares Pharma Inc - Results From Phase I Study Support Advancement of Atrs-1902 to Pivotal Clinical Study Which We Anticipate Starting in Q2 2022.
Revenue is expected to be $47.45 Million
Adjusted EPS is expected to be $0.02

Next Quarter Revenue Guidance is expected to be $45.67 Million
Next Quarter EPS Guidance is expected to be $0.02

More details on our Analysts Page.